KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

GRACIAL TABLETS

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

 

GENERIC NAME:

DESOGESTREL AND ETHINYL ESTRADIOL

 

MANUFACTURER:

N.V. ORAGANON

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

X

 

INDICATIONS:

Contraception

 

SIDE EFFECTS:

melasma

menstrual irregularity

migraine

myocardial infarction

nausea/vomiting

optic neuritis

pancreatitis

peliosis hepatis

photosensitivity

pulmonary embolism

retinal thrombosis

secondary malignancy

stroke

thromboembolism

thrombosis

urticaria

vaginal bleeding

vaginitis

weight gain

abdominal pain

acne vulgaris

alopecia

amenorrhea

anorexia

anxiety

appetite stimulation

azotemia

breakthrough bleeding

breast discharge

breast enlargement

candidiasis

cervical dysplasia

cholecystitis

cholelithiasis

cholestasis

depression

diplopia

edema

elevated hepatic enzymes

erythema nodosum

fluid retention

galactorrhea

gingivitis

headache

hepatitis

hepatoma

hypertension

jaundice

keratoconus

libido decrease

maculopapular rash

mastalgia

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

acquired immunodeficiency syndrome (AIDS)

breast-feeding

children

cholestasis

contact lenses

depression

diabetes mellitus

gallbladder disease

headache

human immunodeficiency virus (HIV) infection

hypercalcemia

hypercholesterolemia

hyperlipidemia

hypertension

hypertriglyceridemia

hypothyroidism

incomplete abortion

menstrual irregularity

migraine

obesity

obstetric delivery

ocular disease

porphyria

renal disease

surgery

systemic lupus erythematosus (SLE)

thyroid disease

tobacco smoking

 

ADULT DOSE:

Contraceptive, systemic or Estrogen-progestin or [Antiendometriotic agent] or [Gonadotropin inhibitor, female, noncontraceptive use] -Twenty-one-day cycle: Oral, 1 tablet a day for twenty-one days commencing on Day 1 of the menstrual cycle or on the first Sunday after the menstrual cycle begins; the next round of treatment is begun on the eighth day after the last tablet of the previous cycle has been taken. Twenty-eight-day cycle: Oral, 1 tablet a day for twenty-eight days commencing on Day 1 of the menstrual cycle, or on the first Sunday after the menstrual cycle begins; the next round of treatment is begun on the day after the last tablet of the previous cycle has been taken. Note: With a Sunday start schedule, the patient should take her first tablet on the first Sunday after the onset of menstruation. If the patient's period begins on a Sunday, she should take her first tablet that same day. With a Day-1 start schedule, the patient should take her first tablet on Day 1 of the menstrual cycle. The last seven tablets of the twenty-eight-day cycle contain no hormones. These seven companion tablets are a different color from those containing hormones. Oral contraceptives may be given continuously or cyclically for endometriosis.

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

 

 

PREVIOUS

  

NEXT